Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3628 - XmaI-RRBS DNA methylation screening resolves breast cancer epigenetic heterogeneity

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Translational Research;  Breast Cancer

Presenters

Aleksandr Tanas

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

A.S. Tanas1, T. Kekeeva2, V.O. Sigin3, E.B. Kuznetsova2, E. Poddubskaya4, I. Trotsenko5, D.V. Zaletaev6, V.V. Strelnikov2

Author affiliations

  • 1 Epigenetics Lab, Research Centre for Medical Genetics, 115478 - Moscow/RU
  • 2 Epigenetics, Research Centre for Medical Genetics, 115478 - Moscow/RU
  • 3 Epigenetics, Research Centre for Medical Genetics, 115522 - Moscow/RU
  • 4 Surgery, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 5 Oncology, Moscow Clinical research Center, 111123 - Moscow/RU
  • 6 Laboratory Of Medical Genetics, Sechenov First Moscow State Medical University, Moscow/RU
More

Resources

Abstract 3628

Background

Breast cancer (BC) heterogeneity calls for molecular subtyping that would assist in personalized treatment. An advantage of DNA methylation markers is that their detection in tumors is not compromised by the presence of normal tissues. With a perspective to develop methylation-based BC diagnostic markers, we have performed a genome-wide DNA methylation profiling of a collection of breast tissues and cell lines.

Methods

XmaI-RRBS method was used to profile DNA methylation of 170 BC samples obtained before chemotherapy, six BC cell lines, and 10 normal breast autopsy specimens. Unsupervised hierarchical cluster analysis was used to discern intrinsic DNA methylation BC subtypes; clustering uncertainty was assessed with pvclust R package using bootstrap permutation approach.

Results

We have identified 10 epigenetic BC subtypes different in the DNA methylation profiles. Of these, BC cell lines constitute a separate extremely high methylated subtype clustering far from any tissues assessed. In turn, BC tissues are classified into two major epigenetic subtypes, high- and low-methylated at the promoter regions of genes. We identified 114 genes that distinguish between high- and low-methylated BC subtypes. Noteworthy are the genes of adenylate cyclases ADCY4, ADCY8 and adenylate cyclase stimulants ADORA2B, ADCYAP1; proteins of cell adhesion and extracellular matrix (CDH4, NRXN2, MXRA5, COMP, integrins A8 & A11, ADAM19; potassium channels (KCNH8, KCNJ2, KCNG1, KCNK10, KCNK17, ATP1A3). More than a third among differentially methylated are homeobox genes (VAX2, TLX3, GSX1, IRX1, FOXC2, FOXE3, NKX6-2, VSX1, SOX21, POU4F1) and genes encoding proteins involved in early development and morphogenesis (ZIC1, SPOCK2, DPYSL3, ATOH1, ITGA8). Expectedly, there is no statistically significant difference in methylation of the classical tumor suppressor genes between epigenetic subtypes of BC, as their abnormal methylation is ubiquitous in cancers and thus non-discriminative between tumor types.

Conclusions

Intrinsically epigenetically heterogeneous BC may be classified into a reasonable number of DNA methylation subtypes, promising the discovery of new diagnostic and prognostic markers, as well as of new therapeutic targets.

Clinical trial identification

Legal entity responsible for the study

Research Centre for Medical Genetics.

Funding

Russian Science Foundation (project No.18-15-00430).

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.